Scientists Use IGF-I To Grow New Membranes Around Neurons

November 03, 1997

NEW ORLEANS -- University of Michigan scientists have used an insulin-like growth factor called IGF-I to stimulate growth of a myelin membrane sheath, similar to a sausage casing, around neurons in a culture dish.

"This is the first evidence to indicate that IGF-I can promote growth of new peripheral nervous system myelin sheaths," according to Eva L. Feldman, associate professor of neurology at the U-M Medical School.

If U-M scientists are able to use IGF-I to regenerate myelin in animals, it will be extremely significant; because without myelin, neurons cannot transmit signals from the brain to peripheral nerves or from nerves back to the brain.

Feldman and U-M research fellow Hsin-Lin Cheng presented the first results from their experiments with IGF-I at the Society for Neuroscience meeting here today (Oct. 27). James W. Russell, lecturer in neurology at the U-M Medical School, is a co-investigator on the project.

Because they stimulate growth of nerves, bone and muscle tissue, growth factors have been the subject of intensive research for the past decade. Scientists believe understanding how growth factors affect neural development could lead to new treatments for neurodegenerative diseases like diabetic neuropathy, multiple sclerosis and amyotrophic lateral sclerosis (ALS). The devastating symptoms of these diseases are caused by the death or degeneration of peripheral nerves. Although several growth factors are currently under study, IGF-I appears to be most effective at inducing myelination and preventing neural cell death, according to Cheng.

Named for its structural similarity to insulin and its ability to simulate insulin's glucose-lowering properties, IGF-I is produced in the liver and is present in blood serum. During embryological development, IGF-I is found in high concentrations near tiny "bud cells" called Schwann cells which grow long fibers and wrap around neurons to form myelin sheaths. The U-M experiments were designed to determine whether IGF-I triggers this transformation in Schwann cells.

First, U-M scientists removed dorsal root ganglion neurons from newborn rats. The neurons were chemically treated to strip away the myelin sheath and any naturally occurring Schwann cells. The dissected nerves were maintained in a nutrient-rich culture medium. After undifferentiated Schwann cells from rat embryos were added to the cultures, half were bathed in a solution containing high levels of IGF-I.

After six hours, Schwann cells in the IGF-I solution started extending long feelers toward the rat neurons," Feldman said. "After 12 hours, most feelers were attached and had started wrapping around the fibers. After 48 hours, 50 percent of the neurons in the IGF-I-supplemented cultures had a myelin sheath and looked just like freshly dissected dorsal rat ganglia. No myelination occurred in control cultures which did not receive IGF-I."

"The results suggest IGF-I promotes myelination by triggering a series of biochemical changes which help Schwann cells move and attach to nerve fibers," Russell said. U-M scientists are currently testing IGF-I's ability to stimulate myelination and regenerate nerves in adult rats with neural damage, according to Feldman. "One major problem is targeting delivery of the growth factor to the injured area in the animal," she said. "If we can find a delivery mechanism to get the right concentration of IGF-I to the site of injury, we may be able to regenerate nerves or prevent them from dying."

Research funding for the U-M study was provided by the National Institutes of Health, the American Diabetes Association and the Juvenile Diabetes Foundation.

University of Michigan

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to